Depression is associated with reduced levels of the monoamines in the brain, such as noradrenaline. The selective noradrenaline re-uptake inhibitors (NRIs) are thought to restore the levels of noradrenaline in the synaptic cleft by binding at the noradrenaline re-uptake transporter preventing the re-uptake and subsequent degradation of noradrenaline. This re-uptake blockade leads to the accumulation of noradrenaline in the synaptic cleft and the concentration of noradrenaline returns to within the normal range. This action of NRIs is though to contribute to the alleviation of the symptoms of depression. In the presence of the NRI, small amounts of noradrenaline continue to be degraded in the synaptic cleft.
Permissions for creative use of the resources from Neurotorium
Permission is granted to download images, slides and videos and use them in your own presentations, provided that copyright notices and the Neurotorium logo are not hidden or removed. For use in publications and on websites, proper attribution must be provided together with a link to Neurotorium.org